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ABSTRACT
Increased scientific attention given to cannabis in the United States has particular relevance for its
domestic HIV care population, given that evidence exists for both cannabis as a therapeutic agent
and cannabis use disorder (CUD) as a barrier to antiretroviral medication adherence. It is critical to
identify relative risk for CUD among demographic subgroups of HIV patients, as this will inform
detection and intervention efforts. A Center For AIDS Research Network of Integrated Clinical
Systems cohort (N = 10,652) of HIV-positive adults linked to care at seven United State sites was
examined for this purpose. Based on a patient-report instrument with validated diagnostic
threshold for CUD, the prevalence of recent cannabis use and corresponding conditional
probabilities for CUD were calculated for the aggregate sample and demographic subgroups.
Generalized estimating equations then tested models directly examining patient demographic
indices as predictors of CUD, while controlling for history and geography. Conditional probability
of CUD among cannabis-using patients was 49%, with the highest conditional probabilities
among demographic subgroups of young adults and those with non-specified sexual orientation
(67–69%) and the lowest conditional probability among females and those 50+ years of age
(42% apiece). Similarly, youthful age and male gender emerged as robust multivariate model
predictors of CUD. In the context of increasingly lenient policies for use of cannabis as a
therapeutic agent for chronic conditions like HIV/AIDS, current study findings offer needed
direction in terms of specifying targeted patient groups in HIV care on whom resources for
enhanced surveillance and intervention efforts will be most impactful.
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Increased scientific attention to cannabis encompasses
its potential as a therapeutic agent for some health con-
ditions and impetus to public health challenges. Both
sides of this pendulum impact persons living with
HIV/AIDS (PLWHA). Cannabis has benefits for mana-
ging weight loss, neuropathy, nausea, and pain (Abrams
et al., 2007; Cohen, Heinz, Ilgen, & Bonn-Miller, 2016; de
Jong, Prentiss, McFarland, Machekano, & Israelski, 2005;
Lutge, Gray, & Siegfried, 2013), yet cannabis use disorder
(CUD) is linked to poor antiretroviral medication adher-
ence and virologic outcomes (Bonn-Miller, Oser,
Bucossi, & Trafton, 2014). In the United States, a 23%
cannabis use rate among PLWHA more than triples
that of the general population (SAMHSA, 2011), though
estimates do vary by demography (Hosek, Harper, &
Domanico, 2005; Marshall et al., 2015). That some
PLWHA use cannabis to effectively manage aspects of
their health (Fogarty et al., 2007; Furler, Einarson, Mill-
son, Walmsley, & Bendayan, 2004) and others develop a
dependence syndrome broadly characteristic of that seen
for alcohol, tobacco, and illicit drugs (Budney & Hughes,
2006) underscores a need to identify HIV care enrollees
at-risk for CUD.
Lack of diagnostic specificity and caveats common to
single-site trials (i.e., selection bias, geographic isolation,
historical artifact) have limited the evidence regarding
the domestic prevalence of CUD in extant HIV care lit-
erature. However, recent work (Hartzler et al., 2016),
based on a 10,000+ Center For AIDS Research Network
of Integrated Clinical Systems (CNICS) cohort, more
conclusively estimates CUD prevalence at 31%. The cur-
rent study seeks to document lifetime prevalence rates of
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cannabis use, conditional probabilities of CUD among
cannabis users, and demographic predictors of CUD in
this CNICS cohort. Given ongoing movement toward
more lenient cannabis policies for specified medical con-
ditions including HIV/AIDS, findings may identify HIV
care enrollees for whom targeted surveillance and inter-
vention efforts will be most impactful.
Methods
This report utilized CNICS (2016), an open access plat-
form initiated in 1995 for longitudinal observation of
PLWHA linked to care. Available data derive from docu-
mentation of patient care visits, medication/laboratory
information, and patient-reports collected via web-
based survey. Continual integration of data from seven
CNICS-affiliate sites enabled analyses of cannabis use
rates as well as conditional probabilities and demo-
graphic predictors of CUD without sampling biases
and surrogate endpoints inherent in clinical trials
(Hughes, 2006).
Data sources
This work is restricted to patient demography and 90-
day retrospective reporting on the Alcohol, Smoking,
and Substance Involvement Test [ASSIST (Humeniuk
et al., 2008)]. Patient demography included age, gender,
ethnicity, race, transgender status, and sexual orientation
(the latter collected only among recent enrollees at three
sites). Cannabis reporting specified: (1) an “involvement
score” comprised endorsed dependence symptoms (e.g.,
inability to cut down; craving; consequent role failure;
health, social, legal, or financial problems) whereby a
validated diagnostic threshold identified cases of CUD
(Humeniuk et al., 2008), and (2) prevalence of lifetime
use whereby conditional probabilities of CUD were
then calculated.
Participants
The cohort (N = 10,652) completed a patient-report
battery at a routine clinic visit between 01 January 2007
and 31 December 2014. The CNICS-affiliate sites were
at Harvard University, Johns Hopkins University, Univer-
sity of Alabama-Birmingham, University of California-
San Diego, University of California-San Francisco,
University of North Carolina-Chapel Hill, and University
of Washington. Patients deemed medically unstable,
appearing intoxicated, evidencing significant cognitive
impairment, or unable to speak English or Spanish did
not complete the assessment.
Analytic strategy
Initial review of distributional properties for patient
demography prompted decisions to: (1) create age
groups (i.e., 18–29, 30–39, 40–49, 50+ years), (2) trans-
form race and ethnicity to a single “race/ethnicity”
index (non-Hispanic White, non-Hispanic Black, Hispa-
nic, and Other), and (3) retain transgender status and
sexual orientation for descriptive analyses only, given
low base rate (<1%) of affirmative response for the for-
mer and poor demographic representativeness for the
latter. Prevalence of lifetime cannabis use and con-
ditional probability of CUD among reported cannabis
users were computed for the aggregate sample and by
demographic indices.
Given the nested multisite design, a set of generalized
estimating equations (GEEs) tested population-average
models for a logistic outcome (CUD, no CUD) while
accounting for the non-independence of observations
among site enrollees (Hubbard et al., 2010). All models
specified robust covariance structure, given the large
aggregate sample size. Preliminary models revealed sig-
nificant geographical variance in CUD rate among the
CNICS sites, and historical variance in CUD rate
among the four biennia (i.e., 2007–2008, 2009–2010,
2011–2012, 2013–2014) during which substance use
disorder (SUD) assessment occurred. Thus, site and
assessment biennia were included as covariates in a
multivariate model. Likewise, preliminary models con-
firmed patient age group, gender, and race/ethnicity as




Age ranged from 18 to 84 years (M = 43.71, SD = 10.62),
distributed as 12% 18–29-year-olds, 22% 30–39-year-
olds, 36% 40–49-year-olds, and 30% 50+ year-olds. Gen-
der was 83% male. Distribution of race/ethnicity was
49% Non-Hispanic White, 34% Non-Hispanic Black,
13% Hispanic, and 4% Other. Less than 1% affirmed
transgender status. In the subsample (n = 1716) self-
reporting sexual orientation, 75% endorsed “Lesbian,
Gay, or Homosexual”, 16% “Straight or Heterosexual”,
6% “Bisexual”, 2% “Something Else”, and 2% “Don’t
Know”. Table 1 notes the corresponding subsample sizes.
Prevalence of prior cannabis use and conditional
probability of CUD
Table 1 also notes for the aggregate sample and each
demographic index the prevalence of lifetime cannabis
use and corresponding conditional probability of CUD.
A majority reported cannabis use, with conditional prob-
ability of CUD approaching 50%. Prior cannabis use was
particularly prevalent among those endorsing “Lesbian,
Gay, or Homosexual” and “Bisexual” orientations (79%
apiece) as well as Non-Hispanic Whites (73%). Con-
ditional probability of CUD was most concentrated
among 18–29-year-olds (67%) and two non-specified
sexual orientation categories (i.e., “something else”,
“don’t know”) (67–69%).
Multivariate prediction of CUDs
Overall model statistics revealed several effects. One was
age group, Wald X2 (3) = 22.55, p < .001, though with
non-significant interactions with site and assessment
biennia. Higher CUD rate was indicated among younger
age groups relative to 50+ year-olds. Another effect was
gender, Wald X2 (1) = 32.97, p < .001, with gender × site
interaction, Wald X2 (1) = 6.42, p < .05, and gender ×
assessment bienna interaction, Wald X2 (1) = 4.40,
p < .05. The CUD rate was higher among males compared
to females. Upon closer examination, the gender effect
was substantive (>10% points) at three sites, modest
(3–8% points) at three sites, and absent at the remaining
site. Further, the gender effect was substantive (12–16%
points) in 2007–2012 but more modest (8% points) in
2013–2014. There was also a race/ethnicity effect, Wald
X2 (3) = 36.41, p < .001, and race/ethnicity × assessment
biennia interaction,Wald X2 (3) 13.27, p < .01. Differences
were modest between the “Other” referent group and
Non-Hispanic Whites, Non-Hispanic Blacks, and Hispa-
nics. Race/ethnicity variance was greatest in 2007–2008
(12–20% points), but attenuated in all subsequent bienna
(4–8% points). Table 2 presents beta values with 95% con-
fidence interval limits as well as corresponding standard
errors, Wald X2 values, and odds-ratios with 95% confi-
dence interval limits for the multivariate model.
Discussion
In this multiregional CNICS cohort, 49% of lifetime can-
nabis users screened positive for CUD – a rate clearly
exceeding the 12–36% range reported of past-year can-
nabis users in community sampling efforts (Grucza,









Aggregate sample 10,652 6587 (62%) 49%
Patient demography
Age group
18–29 years 1254 810 (65%) 67%
30–39 years 2310 1465 (63%) 55%
40–49 years 3901 2448 (63%) 46%
50+ years 3187 1864 (59%) 42%
Gender
Male 8882 5815 (66%) 50%




5278 3844 (73%) 47%
Non-Hispanic
Black
3632 1788 (49%) 52%
Hispanic 1270 686 (54%) 54%
Other 472 269 (57%) 49%
Transgender
Yes 87 49 (56%) 47%
No 10,565 6538 (62%) 49%
Sexual orientation (n = 1716)
Lesbian, Gay, or
Homosexual
1280 1007 (79%) 48%
Straight or
Heterosexual
278 175 (63%) 53%
Bisexual 95 75 (79%) 56%
“Something Else” 34 29 (85%) 69%
“Don’t Know” 29 12 (41%) 67%
Sample consists of HIV+ persons enrolled in services and completing a
patient-report assessment between 01 January 2007 and 31 December
2014; patient demography based on self-report; sexual orientation collected
at three of the seven CNICS sites since 2012; “prior use of cannabis” based
on patient-reporting on the ASSIST; cases of CUD identified via validated
diagnostic threshold for ASSIST cannabis involvement scores.
Table 2. Multivariate prediction of cannabis use disorder.
Beta value 95% CI (lower, upper) Standard error Wald X2 (1) Odds-ratio 95% CI (lower, upper)
Age group
18–29 years 1.27 (.70, 1.83) .29 19.44*** 3.54 (2.02, 6.22)
30–39 years .56 (.09, 1.02) .24 5.38* 1.74 (1.09, 2.78)
40–49 years .17 (−.25, .59) .21 .62 1.18 (.78, 1.80)
50+ years (referent) 0 1.00
Gender
Male 1.54 (1.01, 2.06) .27 32.97*** 4.64 (2.75, 7.84)
Female (referent) 0 1.00
Race/ethnicity
Non-hispanic White .63 (−.37, 1.63) .51 1.53, ns 1.88 (.69, 5.11)
Non-hispanic Black −.48 (−1.49, .54) .52 .85, ns .62 (.22, 1.72)
Hispanic −.25 (−1.51, 1.01) .64 .15, ns .78 (.22, 2.76)
Other (referent) 0 1.00
Notes: Based on aggregate sample of N = 10,652 of HIV+ persons enrolled in services and completing a patient-report assessment between 01 January 2007 and
31 December 2014; patient demography based on self-report; cases of CUD identified via validated diagnostic threshold for ASSIST cannabis involvement
scores; odds-ratios reflect likelihood of CUD relative to the indicated referent category; CNICS enrollment site and assessment biennia (i.e., 2007–2008,
2009–2010, 2011–2012, 2013–2014) included as covariates; ***p < .001, **p < .01, *p < .05.
Agrawal, Krauss, Cavazos-Rehg, & Bierut, 2016; Hasin
et al., 2016). Study findings include greater CUD preva-
lence among demographic subgroups of young adults
and those with non-specified sexual orientation, with
young adulthood and male gender emerging as multi-
variate model predictors of CUD. Findings concerning
influences of patient age and gender on CUD prevalence
also mirror those of community sampling efforts,
whereas absence of clear race/ethnicity influences adds
to an equivocal pattern of related results (Mimiaga
et al., 2013; Wu et al., 2013). Based on sensitivity ana-
lyses, greater CUD prevalence among those with non-
specified sexual orientation is consistent with morbidity
findings in broader SUD literature (Lee et al., 2015;
Mereish, Lee, Gamarel, Zaller, & Operario, 2015).
Study caveats bear mentioning. These include: (1) set-
ting representativeness, given that these are all univer-
sity-based sites, (2) selection bias, as data collection
that excluded those appearing intoxicated, and (3) omis-
sion of demographic indicators (i.e., education, employ-
ment, income) that interact with substance abuse to
influence HIV course and outcome (Oldenburg, Perez-
Brumer, & Reisner, 2014). Influence of such caveats
may be mitigated by the size and diversity of this
CNICS cohort, secure procedures whereby patient-
reports of cannabis-related behavior were gathered,
and use of an established patient-report instrument
with diagnostic threshold to identify cases of CUD for
which there is strong, cross-cultural empirical validation.
Conclusions
This study documents nearly half of cannabis-using HIV
care enrollees as having CUD, identifies subgroups
wherein CUD concentration is greater, and specifies
CUD predictors among patient demographic indices.
Study findings are timely, as balancing of the aforemen-
tioned pendulum that cannabis presents as both thera-
peutic agent and drug of abuse for PLWHA is
continually challenged by progressive shifts in legislative
policy (Pacula, Hunt, & Boustead, 2014). Such policies
increase the need for CUD surveillance and intervention
efforts in domestic HIV care settings. Given existing
resource challenges faced by many HIV care settings,
these findings may inform patient subgroups on whom
surveillance and intervention efforts may focus.
Acknowledgements
The content of this report is solely the responsibility of the
authors and does not necessarily represent the official views
of the National Institute of Health. The authors thank Julia
C. Dombrowski for her review and comments on an initial
draft of the manuscript, as well as the providers and patients
from the CNICS sites for their participation in the data
collection.
Disclosure statement
No potential conflict of interest was reported by the authors.
Funding
This work was sponsored by the University of Washington
Alcohol & Drug Abuse Institute with support from the
Washington State I-502 Dedicated Marijuana Fund, and by
the National Institute on Drug Abuse under R03 DA039719.
CNICS is funded by National Institute of Allergy and Infec-
tious Diseases under R24 AI067039, at University of Alabama
at Birmingham (P30 AI027767), University of Washington
(P30 AI027757), University of California San Diego (P30
AI036214), University of California San Francisco (P30
AI027763), Case Western Reserve University (P30
AI036219), Johns Hopkins University (P30 AI094189, U01
DA036935), Harvard University (P30 AI060354), and Univer-
sity of North Carolina at Chapel Hill (P30 AI50410).
References
Abrams, D. I., Jay, C. A., Shade, S. B., Vizoso, H., Reda, H.,
Press, S.,… Peterson, K. L. (2007). Cannabis in painful
HIV-associated sensory neuropathy: A randomized pla-
cebo-controlled trial. Neurology, 68, 515–521.
Bonn-Miller, M. O., Oser, M. L., Bucossi, M. M., & Trafton, J.
A. (2014). Cannabis use and HIV antiretroviral therapy
adherence and HIV-related symptoms. Journal of
Behavioral Medicine, 37, 1–10.
Budney, A. J., & Hughes, J. R. (2006). The cannabis withdrawal
syndrome. Current Opinion in Psychiatry, 19(3), 233–238.
CNICS. (2016). CFAR Network of Integrated Clinical Systems.
Retrieved May 16, 2016, from www.uab.edu/cnics
Cohen, N. L., Heinz, A. J., Ilgen, M., & Bonn-Miller, M. O.
(2016). Pain, cannabis species, and cannabis use disorders.
Journal of Studies on Alcohol and Drugs, 77, 515–520.
Fogarty, A., Rawstorne, P., Prestage, G., Crawford, J., Grierson,
J., & Kippax, S. (2007). Marijuana as therapy for people liv-
ing with HIV/AIDS: Social and health aspects. AIDS Care,
19, 295–301.
Furler, M. D., Einarson, T. R., Millson, M., Walmsley, S., &
Bendayan, R. (2004). Medicinal and recreational marijuana
use by patients infected with HIV. AIDS Patient Care and
STDs, 18(4), 215–228.
Grucza, R. A., Agrawal, A., Krauss, M. J., Cavazos-Rehg, P. A.,
& Bierut, L. J. (2016). Recent trends in the prevalence of
marijuana use and associated disorders in the United
States. JAMA Psychiatry, 73(3), 300–301.
Hartzler, B., Dombrowski, J. C., Crane, H. M., Eron, J. J., Jr.,
Geng, E. H., Mathews, W. C.,…Donovan, D. M. (2016).
Prevalence and predictors of substance use disorders
among HIV care enrollees in the United States. AIDS and
Behavior. Advance online publication. doi:10.1007/s10461-
016-1584-6
Hasin, D. S., Kerridge, B. T., Saha, T. D., Huang, B., Pickering,
R. P., Smith, S. M.,…Grant, B. F. (2016). Prevalence and
correlates of DSM-5 cannabis use disorder, 2012–2013:
Findings from the National Epidemiologic Survey on
Alcohol and Related Conditions-III. American Journal of
Psychiatry, 173(6), 588–599.
Hosek, S. G., Harper, G. W., & Domanico, R. (2005).
Predictors of medication adherence among HIV-
infected youth. Psychology, Health, & Medicine, 10,
166–179.
Hubbard, A. E., Ahern, J., Fleischer, N. L., Van der Laan, M.,
Lippman, S. A., Jewell, N.,… Santariano, W. A. (2010). To
GEE or not to GEE: Comparing population average and
mixed models for estimating the associations between
neighborhood risk factors and health. Epidemiology, 21,
467–474.
Hughes, M. D. (2006). Initial treatment of HIV infection:
Randomized trials with clinical endpoints are still needed.
Journal of Infectious Diseases, 194, 542–544.
Humeniuk, R., Ali, R., Babor, T. F., Farrell, M., Formigoni, M.
L., Jittiwuikarn, J.,… Simon, S. (2008). Validation of the
alcohol, smoking, and substance involvement screening
test (ASSIST). Addiction, 103(6), 1039–1047.
de Jong, B. C., Prentiss, D., McFarland, W., Machekano, R., &
Israelski, D. M. (2005). Marijuana use and its association
with adherence to antiretroviral therapy among HIV-
infected persons with moderate to severe nausea. JAIDS,
38(1), 43–46.
Lee, J. H., Gamarel, K. E., Kahler, C. W., Marshall, B. D. L., Van
Den Berg, J. J., Bryant, K. J.,…Operario, D. (2015).
Co-occurring psychiatric and drug use disorders among
sexual minority men with lifetime alcohol use disorders.
Drug and Alcohol Dependence, 151, 167–172.
Lutge, E. E., Gray, A., & Siegfried, N. (2013). The medical use
of cannabis for reducing morbidity and mortality in patients
with HIV/AIDS. Cochrane Database Systematic Review, (4),
article no. doi:10.1002/14651858.CD005175.pub3.
Marshall, B. D. L., Operario, D., Bryant, K. J., Cook, R. L.,
Edelman, E. J., Gaither, J. R.,… Fiellin, D. A. (2015).
Drinking trajectories among HIV-infected men who have
sex with men: A cohort study of United States Veterans.
Drug and Alcohol Dependence, 148, 69–76.
Mereish, E. H., Lee, J. H., Gamarel, K. E., Zaller, N. D., &
Operario, D. (2015). Sexual orientation disparities in psy-
chiatric and drug use disorders among a nationally repre-
sentative sample of women with alcohol use disorders.
Addictive Behaviors, 47, 80–85.
Mimiaga, M. J., Reisner, S. L., Grasso, C., Crane, H. M., Safren,
S. A., Kitahata, M. M.,…Mayer, K. H. (2013). Substance
use among HIV-infected patients engaged in primary care
in the United States: Findings from the Centers for AIDS
Research Network of Integrated Clinical Systems cohort.
American Journal of Public Health, 103(8), 1457–1467.
Oldenburg, C. E., Perez-Brumer, A. G., & Reisner, S. L. (2014).
Poverty matters: Contextualizing the syndemic condition of
psychological factors and newly diagnosed HIV infection in
the United States. AIDS, 28(18), 2763–2769.
Pacula, R. L., Hunt, P., & Boustead, A. (2014). Words can be
deceiving: A review of variation among legally effective
medical marijuana laws in the United States. Journal of
Drug Policy Analysis, 7(1), 1–19.
SAMHSA. (2011). Results from the 2010 National Household
Survey on Drug Use and Health: Summary of National
Findings. NSDUH Series H-41. Rockville, MD.
Wu, L. T., Blazer, D. G., Gersing, K. R., Burchett, B., Swartz, M.
S., & Mannelli, P. (2013). Comorbid substance use disorders
with other Axis I and II mental disorders among treatment-
seeking Asian Americans, Native Hawaiians/Pacific
Islanders, and mixed-race people. Journal of Psychiatric
Research, 47, 1940–1948.
